GlassScriptPhysician profile
Sarah Jo Boucher
NPI 1962757310
$2,893.37
in general payments reported to CMS, 2019-2025
32 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $307 · 2023: $570 · 2024: $653 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,351.14 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $402.76 | 2023-2025 | Imfinzi, Tagrisso, Enhertu |
| Abbvie INC. | $283.82 | 2024-2025 | |
| Gilead Sciences, INC. | $251.62 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $228.92 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Janssen Biotech, INC. | $194.75 | 2021-2025 | Erleada, Rybrevant, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $187.14 | 2023-2024 | Ninlaro, Alunbrig |
| Incyte Corporation | $175.27 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Pharmacyclics LLC, An Abbvie Company | $149.04 | 2021-2023 | Imbruvica |
| Seagen INC. | $141.21 | 2022 | |
| Genzyme Corporation | $95.14 | 2022-2025 | |
| Abbott Laboratories | $74.40 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $60.23 | 2025 | Zenpep, Vowst |
| Genentech USA, INC. | $55.65 | 2023-2024 | Alecensa, Lunsumio, Ocrevus |
| Astellas Pharma US INC | $50.56 | 2022-2025 | Vyloy, Padcev |
| Novartis Pharmaceuticals Corporation | $44.79 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $42.96 | 2025 | |
| Novocure INC. | $40.56 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $40.08 | 2024-2025 | |
| Blueprint Medicines Corporation | $39.67 | 2023 | Ayvakit |
| Adc Therapeutics America, INC. | $37.91 | 2025 | |
| Stemline Therapeutics INC. | $37.37 | 2025 | Orserdu |
| Caris Mpi, INC. | $32.80 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $31.23 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Beigene USA, INC. | $24.18 | 2024 | Brukinsa |
| Exelixis INC. | $23.48 | 2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $23.47 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.36 | 2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $22.58 | 2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $22.08 | 2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $20.14 | 2025 | Givlaari |
| Tolmar, INC. | $18.17 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.03 | 2024 | Carvykti, Darzalex, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Boucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.